The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer

Shasha Tao, Montserrat Rojo de la Vega, Eli Chapman, Aikseng Ooi, Donna Zhang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Targeting the transcription factor NRF2 has been recognized as a feasible strategy for cancer prevention and treatment, but many of the mechanistic details underlying its role in cancer development and progression are lacking. Therefore, careful mechanistic studies of the NRF2 pathway in cancer initiation and progression are needed to identify which therapeutic avenue—activation or inhibition—is appropriate in a given context. Moreover, while numerous reports confirm the protective effect of NRF2 activation against chemical carcinogenesis little is known of its role in cancer arising from spontaneous mutations. Here, we tested the effects of NRF2 modulation (activation by sulforaphane or inhibition by brusatol) in lung carcinogenesis using a chemical (vinyl carbamate) model in A/J mice and a genetic (conditional KrasG12D oncogene expression, to simulate spontaneous oncogene mutation) model in C57BL/6J mice. Mice were treated with NRF2 modulators before carcinogen exposure or KrasG12D expression to test the role of NRF2 in cancer initiation, or treated after tumor development to test the role of NRF2 in cancer progression. Lung tissues were analyzed to determine tumor burden, as well as status of NRF2 and KRAS pathways. Additionally, proliferation, apoptosis, and oxidative DNA damage were assessed. Overall, NRF2 activation prevents initiation of chemically induced cancer, but promotes progression of pre-existing tumors regardless of chemical or genetic etiology. Once tumors are initiated, NRF2 inhibition is effective against the progression of chemically and spontaneously induced tumors. These results have important implications for NRF2-targeted cancer prevention and intervention strategies.

Original languageEnglish (US)
Pages (from-to)182-192
Number of pages11
JournalMolecular Carcinogenesis
Volume57
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Lung Neoplasms
Neoplasms
Oncogenes
Carcinogenesis
Lung
Mutation
Tumor Burden
Inbred C57BL Mouse
Carcinogens
DNA Damage
Transcription Factors
Apoptosis

Keywords

  • brusatol
  • carcinogenesis
  • chemoprevention
  • sulforaphane
  • vinyl carbamate

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. / Tao, Shasha; Rojo de la Vega, Montserrat; Chapman, Eli; Ooi, Aikseng; Zhang, Donna.

In: Molecular Carcinogenesis, Vol. 57, No. 2, 01.02.2018, p. 182-192.

Research output: Contribution to journalArticle

@article{bb18dbacfe644adbac5804a9e06890d6,
title = "The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer",
abstract = "Targeting the transcription factor NRF2 has been recognized as a feasible strategy for cancer prevention and treatment, but many of the mechanistic details underlying its role in cancer development and progression are lacking. Therefore, careful mechanistic studies of the NRF2 pathway in cancer initiation and progression are needed to identify which therapeutic avenue—activation or inhibition—is appropriate in a given context. Moreover, while numerous reports confirm the protective effect of NRF2 activation against chemical carcinogenesis little is known of its role in cancer arising from spontaneous mutations. Here, we tested the effects of NRF2 modulation (activation by sulforaphane or inhibition by brusatol) in lung carcinogenesis using a chemical (vinyl carbamate) model in A/J mice and a genetic (conditional KrasG12D oncogene expression, to simulate spontaneous oncogene mutation) model in C57BL/6J mice. Mice were treated with NRF2 modulators before carcinogen exposure or KrasG12D expression to test the role of NRF2 in cancer initiation, or treated after tumor development to test the role of NRF2 in cancer progression. Lung tissues were analyzed to determine tumor burden, as well as status of NRF2 and KRAS pathways. Additionally, proliferation, apoptosis, and oxidative DNA damage were assessed. Overall, NRF2 activation prevents initiation of chemically induced cancer, but promotes progression of pre-existing tumors regardless of chemical or genetic etiology. Once tumors are initiated, NRF2 inhibition is effective against the progression of chemically and spontaneously induced tumors. These results have important implications for NRF2-targeted cancer prevention and intervention strategies.",
keywords = "brusatol, carcinogenesis, chemoprevention, sulforaphane, vinyl carbamate",
author = "Shasha Tao and {Rojo de la Vega}, Montserrat and Eli Chapman and Aikseng Ooi and Donna Zhang",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/mc.22745",
language = "English (US)",
volume = "57",
pages = "182--192",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer

AU - Tao, Shasha

AU - Rojo de la Vega, Montserrat

AU - Chapman, Eli

AU - Ooi, Aikseng

AU - Zhang, Donna

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Targeting the transcription factor NRF2 has been recognized as a feasible strategy for cancer prevention and treatment, but many of the mechanistic details underlying its role in cancer development and progression are lacking. Therefore, careful mechanistic studies of the NRF2 pathway in cancer initiation and progression are needed to identify which therapeutic avenue—activation or inhibition—is appropriate in a given context. Moreover, while numerous reports confirm the protective effect of NRF2 activation against chemical carcinogenesis little is known of its role in cancer arising from spontaneous mutations. Here, we tested the effects of NRF2 modulation (activation by sulforaphane or inhibition by brusatol) in lung carcinogenesis using a chemical (vinyl carbamate) model in A/J mice and a genetic (conditional KrasG12D oncogene expression, to simulate spontaneous oncogene mutation) model in C57BL/6J mice. Mice were treated with NRF2 modulators before carcinogen exposure or KrasG12D expression to test the role of NRF2 in cancer initiation, or treated after tumor development to test the role of NRF2 in cancer progression. Lung tissues were analyzed to determine tumor burden, as well as status of NRF2 and KRAS pathways. Additionally, proliferation, apoptosis, and oxidative DNA damage were assessed. Overall, NRF2 activation prevents initiation of chemically induced cancer, but promotes progression of pre-existing tumors regardless of chemical or genetic etiology. Once tumors are initiated, NRF2 inhibition is effective against the progression of chemically and spontaneously induced tumors. These results have important implications for NRF2-targeted cancer prevention and intervention strategies.

AB - Targeting the transcription factor NRF2 has been recognized as a feasible strategy for cancer prevention and treatment, but many of the mechanistic details underlying its role in cancer development and progression are lacking. Therefore, careful mechanistic studies of the NRF2 pathway in cancer initiation and progression are needed to identify which therapeutic avenue—activation or inhibition—is appropriate in a given context. Moreover, while numerous reports confirm the protective effect of NRF2 activation against chemical carcinogenesis little is known of its role in cancer arising from spontaneous mutations. Here, we tested the effects of NRF2 modulation (activation by sulforaphane or inhibition by brusatol) in lung carcinogenesis using a chemical (vinyl carbamate) model in A/J mice and a genetic (conditional KrasG12D oncogene expression, to simulate spontaneous oncogene mutation) model in C57BL/6J mice. Mice were treated with NRF2 modulators before carcinogen exposure or KrasG12D expression to test the role of NRF2 in cancer initiation, or treated after tumor development to test the role of NRF2 in cancer progression. Lung tissues were analyzed to determine tumor burden, as well as status of NRF2 and KRAS pathways. Additionally, proliferation, apoptosis, and oxidative DNA damage were assessed. Overall, NRF2 activation prevents initiation of chemically induced cancer, but promotes progression of pre-existing tumors regardless of chemical or genetic etiology. Once tumors are initiated, NRF2 inhibition is effective against the progression of chemically and spontaneously induced tumors. These results have important implications for NRF2-targeted cancer prevention and intervention strategies.

KW - brusatol

KW - carcinogenesis

KW - chemoprevention

KW - sulforaphane

KW - vinyl carbamate

UR - http://www.scopus.com/inward/record.url?scp=85040179883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040179883&partnerID=8YFLogxK

U2 - 10.1002/mc.22745

DO - 10.1002/mc.22745

M3 - Article

C2 - 28976703

AN - SCOPUS:85040179883

VL - 57

SP - 182

EP - 192

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 2

ER -